Fisher Biosciences unit, Cellomics, and Evotec Technologies Sign License Agreement
PITTSBURGH, Pa., and HAMBURG, Germany,– Cellomics, Inc., a business unit within the Fisher Biosciences group, and Evotec Technologies GmbH announced today that they have entered into a worldwide, non-exclusive patent license agreement. The agreement will provide Evotec Technologies with Cellomics’ core High Content Screening (HCS) patent portfolio, which includes both broad claims to HCS technology and specific classes of HCS assays such as cytoplasm-nuclear translocation, characterization of cellular toxicity, and receptor internalization. This is a significant extension of the portfolio of cellular biology applications for Evotec Technologies in the area of automated high-throughput HCS systems.
Evotec Technologies and Cellomics are also collaborating to develop and market combined offerings incorporating Cellomics’ and Evotec Technologies’ products as seamless solutions. This offering will enable cell biologists to obtain the highest quality, most productive results in their drug discovery, systems biology and high content screening efforts.
Financial details of the agreement were not disclosed.